The objective of this study is to evaluate the effectiveness of a modified continuous renal replacement therapy (CRRT) protocol in maintaining electrolyte balance in adult patients with acute kidney injury (AKI) admitted to the intensive care unit (ICU).
The study assesses whether the use of continuous venovenous hemodiafiltration (CVVHDF) with post-filter replacement under citrate anticoagulation reduces electrolyte losses and the need for electrolyte supplementation compared with standard dialytic CRRT.
Participants receiving standard CRRT will be compared with those treated with the modified protocol.
The duration of participation corresponds to the period during which CRRT is required. Data collection will cease once CRRT is discontinued.
Age ≥18 years
Admission to the intensive care unit (ICU)
Diagnosis of acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT)
Use of regional citrate anticoagulation during CRRT
Known allergy or intolerance to citrate
Contraindications to citrate anticoagulation (e.g., severe liver failure or severe metabolic disorders affecting citrate metabolism)
Pregnancy or breastfeeding
Sequential
continuous renal replacement therapy
Procedure/SurgeryContinuous renal replacement therapy (CRRT) using regional citrate anticoagulation. Treatment modalities include continuous venovenous hemodialysis (CVVHD) and continuous venovenous hemodiafiltration (CVVHDF) with post-filter replacement, depending on study group assignment.
Total electrolyte supplementation during CRRT
Total amount of electrolyte supplementation administered during continuous renal replacement therapy (CRRT), including potassium, magnesium, and phosphate, expressed as total mmol administered per day (mmol/day)
CRRT circuit lifespan (hours)
Duration of each CRRT circuit, defined as the total time in hours that the extracorporeal circuit remains functional before replacement.
Click on the lead sponsor to view all of their trials.
